Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 4 Study of VPRIV in Treatment-naïve Type 1 Gaucher Disease
2015-001578-17Phase 4Unknown
- Sponsor
- Takeda
- Start
- Dec 2015
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of velaglucerase alfa in Gaucher disease type 1 (GD1), sponsored by Takeda. Primary endpoint: Change in lumbar spine bone mineral density Z-score at 24 months. Status: unknown.
02
Drugs
velaglucerase alfa
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on 2015-001578-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001578-17.